alendronate has been researched along with edetic acid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fleisch, H; Janner, M; Mühlbauer, RC | 1 |
| Chen, IW; deLuna, FA; Lin, JH | 1 |
| Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN | 1 |
| Alferiev, IS; Breuer, E; Cohen, H; Eidelman, N; Golomb, G; Hägele, G; Ornoy, A; Patlas, N; Solomon, V | 1 |
| Farina, AR; Gulino, A; Mackay, AR; Tacconelli, A; Teti, A | 1 |
| Stepan, JJ; Zikan, V | 1 |
| Cappabianca, L; Di Ianni, N; Farina, AR; Gulino, A; Mackay, AR; Merolle, S; Ragone, M; Ruggeri, P | 1 |
1 review(s) available for alendronate and edetic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for alendronate and edetic acid
| Article | Year |
|---|---|
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Chelating Agents; Collagen Type I; Edetic Acid; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Risedronic Acid | 2009 |
6 other study(ies) available for alendronate and edetic acid
| Article | Year |
|---|---|
Sodium EDTA enhances intestinal absorption of two bisphosphonates.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Calcium; Clodronic Acid; Diphosphonates; Edetic Acid; Intestinal Absorption; Male; Rats; Rats, Inbred Strains | 1991 |
On the absorption of alendronate in rats.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Carbon Radioisotopes; Digestive System; Diphosphonates; Edetic Acid; Gastrointestinal Transit; Glucose; Hydrogen-Ion Concentration; Injections, Intravenous; Intestinal Absorption; Male; Peptic Ulcer; Rats; Rats, Sprague-Dawley | 1994 |
Nonclinical model for assessing gastric effects of bisphosphonates.
Topics: Alendronate; Animals; Chelating Agents; Diphosphonates; Edetic Acid; Egtazic Acid; Etidronic Acid; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach | 1997 |
Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Betaine; Bone and Bones; Bone Resorption; Calcinosis; Chelating Agents; Diphosphonates; Edetic Acid; Hindlimb; Hydroxyapatites; Male; Pamidronate; Protein Synthesis Inhibitors; Rats; Structure-Activity Relationship; Tetracycline | 1998 |
Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate.
Topics: Alendronate; Cations; Chelating Agents; Diphosphonates; Edetic Acid; Fibrinolysin; Gelatinases; Humans; Matrix Metalloproteinase 2; Metalloendopeptidases; Protease Inhibitors; Tissue Inhibitor of Metalloproteinase-2; Tumor Cells, Cultured | 1998 |
Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.
Topics: Alendronate; Catalysis; Catalytic Domain; Cations; Cell Line, Tumor; Chelating Agents; Dose-Response Relationship, Drug; Edetic Acid; Fibrinolysin; Hemopexin; Humans; Matrix Metalloproteinase 9; Plasminogen; Protein Structure, Tertiary; Recombinant Proteins | 2012 |